Naomi R. Kass BA , Elizabeth Ledbetter BS , Timothy A. Erickson PhD , Jonathan M. Yarimi MD , Anthony Zoghbi MD , Eyal Muscal MD , Kristy O. Murray DVM, PhD , Kristen S. Fisher DO , Alexander J. Sandweiss MD, PhD
{"title":"Pediatric N-Methyl-d-Aspartate Receptor Encephalitis is Differentiated From Encephalitis Mimickers by Early Elevated Blood Pressure","authors":"Naomi R. Kass BA , Elizabeth Ledbetter BS , Timothy A. Erickson PhD , Jonathan M. Yarimi MD , Anthony Zoghbi MD , Eyal Muscal MD , Kristy O. Murray DVM, PhD , Kristen S. Fisher DO , Alexander J. Sandweiss MD, PhD","doi":"10.1016/j.pediatrneurol.2025.08.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pediatric <em>N</em>-methyl-<span>d</span>-aspartate receptor (NMDAR) encephalitis (pNMDARE) is characterized by severe neuropsychiatric symptoms and prolonged hospitalization and recovery. Early pNMDARE diagnosis is complicated by neuropsychiatric mimickers requiring strong clinical suspicion to escalate to the required lumbar puncture (LP), delaying diagnosis and treatment. Since autonomic dysfunction is a cardinal feature of pNMDARE, we hypothesized that early vital signs serve as a potential noninvasive biomarker to screen for appropriate escalation of pNMDARE evaluation.</div></div><div><h3>Methods</h3><div>This is a retrospective, case-control analysis of patients with pNMDARE between 2021 and 2023. Patients diagnosed with pNMDARE as determined by clinical presentation and positive cerebrospinal fluid (CSF) antibodies (Abs) were compared with control subjects who were evaluated for pNMDARE, including an LP, but were negative.</div></div><div><h3>Results</h3><div>Fifty-seven patients were included for analysis: 23 diagnosed with pNMDARE and 34 without. When standardized for age, sex, and height, the pNMDARE group had higher systolic and diastolic BP percentiles (BP%ile) compared with the anti-NMDAR Ab–negative group (systolic BP%: 95.0% ± 2.3% vs 68.8% ± 4.4%, respectively, <em>P</em> < 0.001; diastolic BP%: 88.3% ± 2.8% vs 61.3% ± 4.1%, respectively; <em>P</em> < 0.001). A receiver operator curve indicated that the shortest Euclidian distance for systolic BP%ile was 99<sup>th</sup>%ile (specificity, 85.3%; sensitivity, 65.2% <em>P</em> < 0.0001) and for diastolic BP%ile was 88.5<sup>th</sup>%ile (specificity, 73.5%; sensitivity, 65.2%; <em>P</em> < 0.005).</div></div><div><h3>Conclusions</h3><div>Although CSF Ab is required for the diagnosis of pNMDARE, screening tools may help hasten clinical suspicion for the need for an LP. We identified elevated BP as a potential differentiating early clinical marker specific to pNMDARE. This fact corroborates our current understanding of dysautonomia in pNMDARE and provides a potential clinical marker suitable for future research and validation.</div></div>","PeriodicalId":19956,"journal":{"name":"Pediatric neurology","volume":"172 ","pages":"Pages 71-77"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887899425002358","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Pediatric N-methyl-d-aspartate receptor (NMDAR) encephalitis (pNMDARE) is characterized by severe neuropsychiatric symptoms and prolonged hospitalization and recovery. Early pNMDARE diagnosis is complicated by neuropsychiatric mimickers requiring strong clinical suspicion to escalate to the required lumbar puncture (LP), delaying diagnosis and treatment. Since autonomic dysfunction is a cardinal feature of pNMDARE, we hypothesized that early vital signs serve as a potential noninvasive biomarker to screen for appropriate escalation of pNMDARE evaluation.
Methods
This is a retrospective, case-control analysis of patients with pNMDARE between 2021 and 2023. Patients diagnosed with pNMDARE as determined by clinical presentation and positive cerebrospinal fluid (CSF) antibodies (Abs) were compared with control subjects who were evaluated for pNMDARE, including an LP, but were negative.
Results
Fifty-seven patients were included for analysis: 23 diagnosed with pNMDARE and 34 without. When standardized for age, sex, and height, the pNMDARE group had higher systolic and diastolic BP percentiles (BP%ile) compared with the anti-NMDAR Ab–negative group (systolic BP%: 95.0% ± 2.3% vs 68.8% ± 4.4%, respectively, P < 0.001; diastolic BP%: 88.3% ± 2.8% vs 61.3% ± 4.1%, respectively; P < 0.001). A receiver operator curve indicated that the shortest Euclidian distance for systolic BP%ile was 99th%ile (specificity, 85.3%; sensitivity, 65.2% P < 0.0001) and for diastolic BP%ile was 88.5th%ile (specificity, 73.5%; sensitivity, 65.2%; P < 0.005).
Conclusions
Although CSF Ab is required for the diagnosis of pNMDARE, screening tools may help hasten clinical suspicion for the need for an LP. We identified elevated BP as a potential differentiating early clinical marker specific to pNMDARE. This fact corroborates our current understanding of dysautonomia in pNMDARE and provides a potential clinical marker suitable for future research and validation.
期刊介绍:
Pediatric Neurology publishes timely peer-reviewed clinical and research articles covering all aspects of the developing nervous system.
Pediatric Neurology features up-to-the-minute publication of the latest advances in the diagnosis, management, and treatment of pediatric neurologic disorders. The journal''s editor, E. Steve Roach, in conjunction with the team of Associate Editors, heads an internationally recognized editorial board, ensuring the most authoritative and extensive coverage of the field. Among the topics covered are: epilepsy, mitochondrial diseases, congenital malformations, chromosomopathies, peripheral neuropathies, perinatal and childhood stroke, cerebral palsy, as well as other diseases affecting the developing nervous system.